Skip to content

The Effect of Perioperative Pregabalin on the Incidence of Chronic Post-thoracotomy Pain Syndrome

A Multicenter Prospective Randomized Double-blind Placebo Controlled Trial Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00998816
Enrollment
0
Registered
2009-10-21
Start date
2012-05-31
Completion date
2014-10-31
Last updated
2012-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Keywords

thoracotomy, chronic, pain, pregabalin, Lyrica

Brief summary

Pregabalin, administered prior to and following lateral thoracotomy surgery will reduce the likelihood of chronic post-thoracotomy pain syndrome (CPTPS).

Detailed description

A total of 200 patients scheduled for lateral thoracotomy will be randomly assigned to receive either placebo or 150 mg pregabalin (Lyrica)1 hour prior to surgery, 12 hr after surgery and then every 12 hr for an additional 10 days. While in the hospital, patients will be assessed for pain intensity, satisfaction and side effects. Patients will be re-assessed at 2, 4 and 6 months following surgery.

Interventions

DRUGPregabalin

pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.

Sponsors

McMaster University
CollaboratorOTHER
Queen's University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Elective open thoracotomy for primary thoracic surgery, understanding and provision of written informed consent, ASA class I II or III

Exclusion criteria

* Inability ot adhere to study protocol: * intolerance or hypersensitivity to any agents to be used in the study, contraindication to thoracic epidural placement * inability to respond to the study questionnaire * renal insufficiency(serum creatinine \> 1.5 upper limit of normal) * Body Mass index \> 40 * planned post-operative ventilation. * Confounding procedural factors which might affect validity of data: * previous ipsilateral thoracotomy * surgery for tumor extending into the chest wall * rest pain in proposed surgical area pre-operatively * chest tube in situ at time of surgery * requirement for second thoracotomy or re-occurrence of disease after surgery \*isolated pleuroscopy or pleurodesis procedures. * Potential interaction with study medications and patient's current medications: * current alcohol or other substance abuse * chronic steroid use * pre-existing chronic pain requiring chronic analgesic use * history of seizure disorder requiring treatment with an anticonvulsant * current therapy with thiazolidinedione class oral hypoglycemic agents (eg, Actos, Avandia or Avandamet) * history of congestive heart failure * major psychiatric disorder * any contraindication to use of NSAIDs. * Insufficient safety data in the patient population: * patients requiring preoperative assistance or assistive device for ambulation, pregnant or breastfeeding * weight \<50 Kg * dizziness while inpatient.

Design outcomes

Primary

MeasureTime frame
Incidence of chronic post thoracotomy pain syndrome6 months following surgery

Secondary

MeasureTime frame
During hospital stay: pain intensity, PEF and FEV1, patient satisfaction, medication side effects. At 2, 4, and 6 months: pain intensity, pain quality (neuropathic versus other), quality of life, pain interference with daily functionDuring hospital stay and at 2, 4, and 6 months postoperatively

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026